Incorporation of [32p]p; into phosphatidic acid and phosphatidylinositol of hamster epididymal adipocytes was partially inhibited by 3-isobutyl-1-methylxanthine. This effect of 3-isobutyl-1-methylxanthine was antagonized by isopropyl-N6-phenyladenosine but not by 2',5'-dideoxyadenosine, prostaglandin E, or clonidine. N6-Phenylisopropyladenosine did not affect incorporation of [32P]Pi into phosphatidic acid or phosphatidylinositol when 3-isobutyl-1-methylxanthine was not present. In contrast with 3-isobutyl-1-methylxanthine inhibition of [32p]p1 incorporation into phospholipids, which was blocked only by N6-phenylisopropyladenosine, accelerated lipolysis was blocked by prostaglandin E1, clonidine and 2',5'-dideoxyadenosine as well as by N6-phenylisopropyladenosine. Phospholipid labelling was also decreased in the presence of adenosine deaminase, but not in the presence of isoprenaline (isoproterenol). The stimulatory effect of N6-phenylisopropyladenosine on [32p]p1 incorporation into phospholipids in cells exposed to 3-isobutyl-1-methylxanthine was evident as soon as 3min after addition of the adenosine analogue and maximum 10min after its addition.
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As observed by others, [12P]P1 incorporation into phospholipids was increased by the a,-selective agonist methoxamine. The stimulatory effect of methoxamine occurred with a time course similar to that of N6-phenylisopropyladenosine and was present at nearly equal magnitude in the absence or presence of 3-isobutyl-1-methylxanthine. The inhibitory effects of 3-isobutyl-1-methylxanthine and adenosine deaminase on phospholipid labelling are attributed to blockade of the action, or to the enzymic removal, of adenosine formed in and released from the fat-cells during their incubation. Supporting this view is the selective reversal of the actions of 3-isobutyl-1-methylxanthine and of adenosine deaminase by N6-phenylisopropyladenosine. These findings suggest an important role for endogenous adenosine in regulation of phospholipid turnover in adipocytes.
Many hormones, neurotransmitters and other agents have been found to accelerate the incorporation of ["PIP, into phospholipids, principally phosphatidylinositol and phosphatidic acid (Michell, 1975) . Because the actions of many of these same hormones and neurotransmitters appear to be mediated by an increase in intracellular Ca2+ concentration, partly because of an increase in Ca2+ permeability (Michell, 1975; Michell & Kirk, 1981; Exton, 1981) , the hypothesis has been enunciated that this 'phospholipid effect' is coupled to altert To whom reprint requests should be addressed.
Vol. 212 ations in cell Ca2+, perhaps by modifying membrane Ca2+ conductance (Michell, 1975) . The molecular basis for the phospholipid effect is thought to involve accelerated hydrolysis of phosphatidylinositol to diacylglycerol and inositol phosphates, phosphorylation of the diacylglycerol to phosphatidic acid and subsequent resynthesis of phosphatidylinositol. and Putney et al. (1980) have proposed that the net accumulation of phosphatidic acid after breakdown of phosphatidylinositol initiates an increase in Ca2+ influx, thereby allowing cell Ca2+ to increase. In support of this view is the finding that phosphatidic acid behaves as a Ca2+ ionophore in artificial lipid bilayers (Green et al., 1980) . More recently, another action of phosphatidic acid has become evident. Clark et al. (1980) and Schimmel et al. (1980) reported that exposure of WI-38 fibroblasts and hamster epididymal adipocytes to phosphatidic acid inhibited hormone-stimulated cyclic AMP formation. Both groups raised the possibility that accumulation of phosphatidic acid was intimately involved in hormone attenuation of adenylate cyclase in these cells. In hamster adipocytes, adenosine, a2-receptor-site agonists (e.g. clonidine) and prostaglandin El inhibit cyclic AMP accumulation (Schimmel et al., 1980 (Schimmel et al., , 1981 by lowering activity of adenylate cyclase (Jakobs & Aktories, 1981) , but a role of these agents in regulation of phosphatidic acid formation is uncertain. reported that clonidine had no detectable effect on [32P]P1 incorporation into phospholipids in hamster white adipocytes, but their data were obtained under incubation conditions that allow endogenous adenosine to accumulate and act on the fat-cells during their incubation. Because accumulation of adenosine has been found to interfere with clonidine action on lipolysis and cyclic AMP accumulation in hamster fat-cells (Schimmel et al., 1981) , one might expect to observe clonidine stimulation of phospholipid labelling only in the absence of adenosine. It follows that a more appropriate test of clonidine action on phospholipid turnover should be made with incubation conditions that either prevent adenosine accumulation, such as by addition of adenosine deaminase, or prevent adenosine action, such as with a methylxanthine (Schimmel et al., 1981) . The purpose of the present studies was to determine if clonidine and other anti-lipolytic agents accelerated the turnover of phosphatidylinositol in hamster fat-cells incubated in the presence of 3-isobutyl-1-methylxanthine or adenosine deaminase.
Materials and methods Preparation ofadipocytes
Golden hamsters (90-1Og) were purchased from Charles River Laboratories, Lakeview, NJ, U.S.A., and fed on Purina laboratory chow and tap water ad libitum for at least 1 week before use. They were killed by cervical dislocation, the epididymal fatbodies were removed and adipocytes were prepared by collagenase digestion as previously described (Schimmel et al., 1981) . The adipose tissue from two to four hamsters was minced and placed in plastic vessels containing 5 ml of Krebs-Ringer Hepes [4 -(2 -hydroxyethyl) -1 -piperazine -ethanesulphonic acid] buffer with 5% bovine serum albumin and 1.5mg of collagenase/ml. The composition of the buffer used in all experiments was 115 mM-NaCl, 4.6 mM-KCl, 1.5 mM-CaCl2, 1.4 mM-MgSO4, 1 1 mMNaHCO3 and 30mM-Hepes, adjusted to pH 7.4 after addition of the albumin. After enzymic digestion, the adipocytes were filtered through a silk screen and washed three times with albumin-containing buffer.
Incorporation of [32P]Pi into phospholipids
Fat-cells were incubated in 2 ml of buffer containing lO,Ci of [32P1P/ml for up to 1 h. After incubation the cells were separated from the medium by flotation in silicone PCR Research Chemicals, Gainsville, FL, U.S.A.)-coated Pasteur pipettes. The media was collected for assay of glycerol as previously described (Schimmel et al., 1981) . The cells were washed with 2 ml of 150 mMNaCl buffered with 10mM-phosphate (pH 7. (1977) .
Rates of glycerol production are expressed relative to the weight of dried total cell lipid extracts obtained from samples taken during the distribution of cells into the incubation vessels. Incorporation of 32p into each phospholipid is expressed relative to the amount of phosphatidylcholine phosphate recovered from each plate. Phosphatidylcholine was selected for this purpose, because it is the most prevalent phospholipid and its concentration did not vary in response to hormone treatment.
Materials
Collagenase (type I) was obtained from Worthington Biochemical Corp. Isoprenaline (isoproterenol), 3-isobutyl-1-methylxanthine, adenosine deaminase, prostaglandin El and bovine serum albumin (type V) were from Sigma. Methoxamine was from Burroughs-Wellcome. N6-Phenylisopropyladenosine was from Boehringer-Mannheim. 2',5'-Dideoxyadenosine was from P-L Bio-chemicals. Hepes was from Calbiochem. Clonidine was generously given by Boehringer-Ingelheim. All other chemicals were of reagent grade.
Results
Of the major phospholipids found in hamster fat-cells, only phosphatidylcholine, phosphatidylinositol and phosphatidic acid became significantly (0) (Fig. 1) . When 3-isobutyl-l-methylxanthine (50 ,UM) was present, incorporation of radioactivity into both phospholipids was significantly decreased, but the time course of labelling appeared unaltered. 3-Isobutyl-1-methylxanthine increased the rate of lipolysis, which was also nearly linear during the 60 min incubation (results not shown). Increasing the concentration of 3-isobutyl-l-methylxanthine to greater than 50,UM did not cause a greater inhibition of [32p]p1 incorporation into phospholipid (Fig. 2) , but the rate of lipolysis was increased when higher concentrations of the methylxanthine were present. When the a2-selective adrenergic agonist clonidine was present at a concentration of 10,UM, the stimulation of lipolysis in response to 50 ,UM-3-isobutyl-l-methylxanthine was prevented, and the stimulation caused by 100 uM-3-isobutyl-1-methylxanthine was significantly decreased (P <0.05); lipolysis activated with 1 mM-3-isobutyl-l-methylxanthine was unaffected by this concentration of clondine. In contrast with clonidine antagonism of 3-isobutyl-1-methylxanthine-stimulated lipolysis, the a2-adrenergic agonist did not prevent or decrease 3-isobutyl-l-methylxanthine inhibition of [32P]P incorporation into the phospholipids (Fig. 2) .
The data presented in Table 1 compare the effects of 3-isobutyl-1-methylxanthine and isoprenaline on [32p1P1 incorporation into phosphatidic acid and phosphatidylinositol. Although both agents caused a comparable stimulation of lipolysis, only 3-isobutyl-1-methylxanthine inhibited [32p]p; incorporation into phospholipids. Isoprenaline, which increased lipolysis to an extent comparable with that in the presence of 3-isobutyl-1-methylxanthine, caused only a slight decrease in[32P]P1 incorporation into phosphatidic acid and phosphatidylinositol. When 3-isobutyl-1-methylxanthine and isoprenaline were present together, a larger increase in lipolysis was observed that was associated with a decrease in
[132P]P incorporation into phosphatidic acid and phosphatidylinositol that exceeded the decrease in phospholipid labelling observed in the presence of 3-isobutyl-l-methylxanthine alone.
Because the mode of 3-isobutyl-1-methylxanthine action on adipocytes is thought to involve the blockade of adenosine receptors (Londos et al., 1978) , our next experiments sought to determine if 3-isobutyl-1-methylxanthine inhibition of phospholipid labelling could be prevented and reversed by analogues of adenosine. The data presented in Table  2 show that exposure of fat-cells to N6-phenyl- (Table 2) . We have found the time course of the methoxamine effect to be similar to that of N6-phenylisopropyladenosine (results not shown). The data presented in Table 4 show that exposure of fat-cells to adenosine deaminase causes a significant decrease in [32p]p1 incorporation into both phospholipids. As with 3-isobutyl-l-methylxanthine, this effect of adenosine deaminase was antagonized by N6-phenylisopropyladenosine. The stimulation of lipolysis caused by adenosine deaminase, although statistically significant (P < 0.05), was very much less than that observed in cells exposed to 3-isobutyl-l-methylxanthine.
Discussion
The observation, made first by Clark et al. (1980) and then by Schimmel et al. (1980) , that phosphatidic acid can decrease cell cyclic AMP concentrations led to the hypothesis that accelerated formation of this lipid by hydrolysis of phosphatidylinositol may be involved in hormonal attenuation of cyclic AMP generation. The results presented herein and in the preceding paper (Honeyman et al., 1983) , however, are enigmatic -on this point. On one hand, our data indicate stimulation of phosphatidate formation by adenosine, which occurs concomitantly with inhibition of lipolysis and of cyclic AMP accumulation (Schimmel et al., 1980) , and are therefore in accord with a role of phosphatidate in regulation of cyclic AMP formation. In addition, increased accumulation of phosphatidate in cells exposed to phospholipase C (Honeyman et al., 1983) is perhaps the simplest explanation for its well-documented inhibitory effects on lipolysis and accumulation of cyclic AMP (Rodbell & Jones, 1966; Rosenthal & Fain, 1971; Fredholm et aL, 1978) . By similar reasoning, accumulation of phosphatidic acid may be implicated in the cyclic AMP-lowering and anti-lipolytic effects of insulin and oxytocin (T. W. Honeyman, W. Strohsnitter, C. R. Scheid & R. J. Schimmel, unpublished work) . On the other hand, a role of phosphatidic acid in the actions of clonidine and prostaglandin E1 is not supported by the present results documenting a lack of effect of these agents on incorporation of [32p]pI into phosphatidic acid and phosphatidylinositol. A role of phosphatidic acid in mediation of the effects of clonidine and prostaglandin E1 would appear to require postulating formation of this lipid by a reaction not involving phosphorylation of diacylglycerol, such as through a phospholipase D (Kanfer, 1972 ).
The conclusion that adenosine can accelerate phosphatidylinositol labelling in hamster adipocytes derives from the observations that 3-isobutyl-1-methylxanthine and adenosine deaminase decrease
[32p]p1 incorporation into phosphatidic acid and phosphatidylinositol and that this inhibition is reversed selectively by the adenosine analogue N6-phenylisopropyladenosine. We interpret the inhibition of [32p]ps incorporation into phospholipids by 3-isobutyl-1-methylxanthine to be a direct consequence of blockade of adenosine R-type (Daly et al., 1981) receptors on fat-cells and suggest that endogenously formed adenosine constitutes a stimulus for phospholipid turnover. Evidence presented by several laboratories indicates that fat-cells incubated in vitro release adenosine into the media (Schimmel et al., 1981; Schwabe et al., 1973) , which alters the metabolism of the cells by interacting with specific membrane receptors (Trost & Schwabe, 1981) . 3-Isobutyl-1-methylxanthine and other methylxanthines interfere with adenosine action by antagonizing adenosine R-type receptors (Londos et al., 1978; Trost & Schwabe, 1981) . We therefore propose that the degree of ["2p ]p incorporation into phospholipids in 'unstimulated' adipocytes depends on the accumulation of adenosine in the media. Thus the blockade of adenosine action by 3-isobutyl-1-methylxanthine or removal of adenosine with adenosine deaminase decreases phospholipid labelling by removing an endogenous stimulus to phospholipid turnover. N6-Phenylisopropyladenosine is without effect in the absence of 3-isobutyl-1-methylxanthine, because, according to our view, the cells are already maximally stimulated by endogenous adenosine in their cell preparations. also reported that neither adenosine nor N6-phenylisopropyladenosine modified incorporation of [2PIP1 into phospholipids in white fat-cells. In their studies adipocytes were incubated at high density, and it is likely that effects of exogenously added adenosine were not observed because the cells were already maximally stimulated by endogenously formed nucleotide.
An alternative explanation for our results is that the decreased incorporation of [P2p]p into phospholipids in cells exposed to 3-isobutyl-1-methylxanthine results from the intracellular accumulation of non-esterified fatty acids and the lowered ATP concentrations that occur concomitant with accelerated lipolysis in adipocytes (Heindel et al., 1974) . Indeed, reported decreased [2PIP1 incorporation onto phospholipids of rat white fat-cells exposed to the lipolytic stimuli corticotropin, dibutyryl cyclic AMP and isoprenaline. Because the effect of these lipolytic agents on
[32p]p1 incorporation into phospholipids was prevented or decreased by increasing the albumin concentration in the medium, they proposed that lipolytic stimuli lower phospholipid labelling through a mechanism involving increased lipolysis and accumulation of non-esterified fatty acids within fat-cells. Unfortunately, did not include methylxanthines in their study.
The present results do not diminish the importance of intracellular non-esterified fatty acids and ATP as potential mediators of the effects of lipolytic stimuli on phosphatidylinositol and phosphatidic acid labelling. However, a role for non-esterified -fatty acids and ATP in 3-isobutyl-1-methylxanthine
Vol. 212 inhibition of [3"P]P1 incorporation into phospholipids seems unlikely for several reasons. Firstly, the inhibitory effect of 3-isobutyl-1-methylxanthine on phospholipid labelling was evident after only 20min of incubation (Fig. 1) , but cellular accumulation of non-esterified fatty acids would be expected to be minimal at this time (Heindel et al., 1974) . Secondly, the incorporation of ["PIP, into phosphatidic acid was decreased maximally by 50,uM-3-isobutyl-1-methylxanthine, but lipolysis was increased only slightly at this concentration of the methylxanthine (Fig. 2) . Thirdly, 3-isobutyl-1-methylxanthine-accelerated lipolysis was antagonized by clonidine (Fig.  2) , prostaglandin El (Table 2) , 2',5'-dideoxyadenosine (Table 2) and N6-phenylisopropyladenosine, but 3-isobutyl-1-methylxanthine inhibition of [32P]P incorporation into phospholipids was reversed only by N6-phenylisopropyladenosine. Fourthly, when the stimulus for lipolysis was provided by isoprenaline rather than 3-isobutyl-1-methylxanthine, phospholipid labelling was not decreased (Table 1) , even though the rates of lipolysis in the presence of each agent were nearly identical. Lastly, adenosine deaminase decreased phospholipid labelling while causing only a slight increase in lipolysis (Table 4) .
Taken together, these observations show no correlation between the rate of lipolysis and the degree of phospholipid labelling, and therefore argue strongly against the possibility that the effects of 3-isobutyl-l-methylxanthine and N6-phenylisopropyladenosine on [32p]p incorporation into phosphatidylinositol and phosphatidic acid result from changes in lipolysis and the resultant changes in cellular concentrations of non-esterified fatty acids.
As reported first by Daly et al., 1981) . Most of these studies have focused on adenosine stimulation and/or inhibition of adenylate cyclase (Londos et al., 1978; Daly et al., 1981) . Along these lines, several laboratories (Londos et al., 1978; Trost & Stock, 1977) have shown adenosine inhibition of adipocyte adenylate cyclase activity. However, adenosine exerts effects on fat-cells that appear to be unrelated to its effects on the adenylate cyclase-cyclic AMP system. For example, adenosine or N6-phenylisopropyladenosine has been shown to accelerate glucose transport and oxidation by fat-cells (Schwabe et al., 1974) , to activate cyclic AMP phosphodiesterase (Teo et al., 1981) and to activate pyruvate dehydrogenase (Honeyman et al., 1983) . The present paper documents yet another action of adenosine on fatcells that appears to be independent of cyclic AMP, namely acceleration of 32p labelling of phosphatidylinositol and phosphatidic acid. The possibility that the stimulation by adenosine of glucose metabolism, pyruvate dehydrogenase activity and cyclic AMP phosphodiesterase result from stimulated phospholipid turnover is an attractive yet unproven idea. It should be noted, however, that a similar conclusion has been reached in regard to the effects of insulin and other insulin-like agents (Farese et al., 1982; Honeyman et al., 1983) .
